NEW YORK, Aug. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019http://www.reportlinker.com/p0869191/Hepatitis-B-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019
SummaryGlobalData, the industry analysis specialist, has released its new report, "Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global hepatitis B therapeutics market. The report identifies the key trends shaping and driving the global hepatitis B therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hepatitis B therapeutics market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.GlobalData's analysis shows that the global hepatitis B therapeutics market stood at $2,018.7m in 2006 and grew at a Compound Annual Growth Rate (CAGR) of 8.6% to reach $3,056.0m in 2011. GlobalData forecasts that the global hepatitis B therapeutics market will grow at a slow rate with a CAGR of 4.8% over the forecast period to reach $4,441.3m by 2019. The low growth in the global hepatitis B therapeutics market can be attributed to the high vaccination coverage rates in developed countries, resulting in lower incidence rates of hepatitis B. The hepatitis B therapeutics market is also set to witness the patent expiry of most of the nucleoside analogues between 2013 and 2017. The patent expiry of the immunologic Pegasys (peginterferon alfa-2a) in 2018 will, however, not impact the market significantly. The high growth rate in the historic period may be attributed to the launch of Pegasys, Tyzeka (telbivudine), Viread (tenovofir) and Baraclude (entecavir) between 2005 and 2008, and the high Annual Cost of Therapy (ACoT) for the pegylated interferon therapy.
Scope
The report provides information on the key drivers and challenges of the hepatitis B therapeutics market. Its scope includes - - Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan hepatitis B therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as HBsAg release blocker, HBV DNA polymerase inhibitor, HBV DNA polymerase inhibitor and immunomodulator, HBV DNA polymerase inhibitor and microtubule assembly inhibitor, HBV therapeutic vaccine, HBV therapeutic vaccine and HBV DNA polymerase inhibitor, Hydroxymethyl glutarate coenzyme A (HMG-CoA) reductase inhibitor, Immunomodulator, Protease inhibitor and others.- Analysis of the current and future competition in the seven key countries hepatitis B therapeutics market. Key market players covered are GlaxoSmithKline, Bristol-Myers Squibb, Daewoong Pharmaceutical Co., Ltd., Chongqing Jiachen Biotechnology Ltd, Chongqing Tongjunge Co., Ltd., LG Life Sciences, Ltd, Bristol-Myers Squibb Company, Phytrix Inc., Medivir AB, AiCuris GmbH & Co. KG, Gilead Sciences, Inc., VectorLogics, Inc., Genexine Co., Ltd., GenPhar, Inc., Cytheris SA, Bolder Biotechnology, Inc, ImQuest Life Sciences, Aduro BioTech, Agenix Limited, Xenetic Biosciences plc, MOLOGEN AG, NanoBio Corporation, Inbiopro Solutions Pvt. Ltd., Gilead Sciences, Merck & Co. Inc. and Novartis AG, - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the hepatitis B therapeutics market.- Analysis of key recent licensing and partnership agreements in hepatitis B therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global hepatitis B therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global hepatitis B therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What's the next big thing in the global hepatitis B therapeutics market landscape? – Identify, understand and capitalize.
Table of Contents1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 Hepatitis B Therapeutics - Introduction 72.1 Overview 72.2 Epidemiology 82.3 Disease Burden 102.4 Etiology 112.5 Symptoms 132.6 Diagnosis 132.7 Pathophysiology 162.8 Treatment and Management Pattern 192.9 GlobalData Pipeline Report Guidance 223 Hepatitis B Therapeutics - Market Characterization 233.1 Hepatitis B Therapeutics Market Size (2006 - 2011) - Global 233.2 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Global 243.3 Hepatitis B Therapeutics Market Size (2006 - 2011) - The US 253.4 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - The US 263.5 Hepatitis B Therapeutics Market Size (2006 - 2011) - France 273.6 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - France 283.7 Hepatitis B Therapeutics Market Size (2006 - 2011) - Germany 293.8 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Germany 303.9 Hepatitis B Therapeutics Market Size (2006 - 2011) - Italy 313.10 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Italy 323.11 Hepatitis B Therapeutics Market Size (2006 - 2011) - Spain 333.12 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Spain 343.13 Hepatitis B Therapeutics Market Size (2006 - 2011) - The UK 353.14 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - The UK 363.15 Hepatitis B Therapeutics Market Size (2006 - 2011) - Japan 373.16 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Japan 383.17 Drivers and Barriers for the Hepatitis B Therapeutics Market 393.17.1 Drivers for the Hepatitis B Therapeutics Market 393.17.2 Barriers for the Hepatitis B Therapeutics Market 393.18 Opportunity and Unmet Need 403.19 Key Takeaway 414 Hepatitis B Therapeutics - Competitive Assessment 424.1 Overview 424.2 Strategic Competitor Assessment 424.3 Product Profile for the Major Marketed Drugs 434.3.1 Intron A (interferon alpha 2b) 434.3.2 Pegasys (peginterferon alfa-2a) 444.3.3 Baraclude (entecavir) 454.3.4 Tyzeka (telbivudine) 474.3.5 Hepsera (adevofir) 504.3.6 Epivir-HBV (lamivudine) 524.3.7 Viread (tenovofir) 544.4 Key Takeaway 565 Hepatitis B Therapeutics - Pipeline Assessment 575.1 Overview 575.2 Strategic Pipeline Assessment 575.3 Hepatitis B Therapeutics - Pipeline Analysis by Clinical Phase of Development 575.3.1 Hepatitis B Therapeutics - Phase III Clinical Pipeline 585.3.2 Hepatitis B Therapeutics - Phase II Clinical Pipeline 595.3.3 Hepatitis B Therapeutics - Phase I Pipeline 605.3.4 Hepatitis B Therapeutics - Preclinical Phase Pipeline 605.3.5 Hepatitis B Therapeutics - NA Phase Pipeline 605.4 Hepatitis B Therapeutics - Pipeline by Mechanism of Action 615.5 Technology Trends Analytical Framework 625.6 Key Takeaway 626 Hepatitis B Therapeutics - Clinical Trials Mapping 636.1 Overview 636.2 Clinical Trials by Region/Country (The US, EU5 and Japan) 636.3 Clinical Trials by Phase of Clinical Development 646.4 Clinical Trials by Trial Status 656.5 Prominent Sponsors 666.6 Clinical Trials by Sponsors 676.7 Top Companies Participating in Hepatitis B Therapeutics Clinical Trials 686.8 Key Takeaway 697 Hepatitis B Therapeutics - Strategic Assessment 707.1 Key Events Impacting the Future Market 707.2 Future Market Competition Scenario 708 Hepatitis B Therapeutics - Future Players 728.1 Introduction 728.2 Company Profiles 728.2.1 Bristol-Myers Squibb Company 728.2.2 Gilead Sciences 748.2.3 GlaxoSmithKline Plc 758.2.4 F. Hoffmann-La Roche 778.2.5 Merck & Co. Inc. 788.2.6 Novartis AG 798.3 Other Companies 808.4 Key Takeaway 849 Hepatitis B Therapeutics - Licensing & Partnership Deals 8510 Hepatitis B Therapeutics - Appendix 9610.1 Market Definitions 9610.2 Abbreviations 9610.3 Research Methodology 9810.3.1 Coverage 9810.3.2 Secondary Research 9810.3.3 Forecasting 9910.3.4 Primary Research 10110.3.5 Expert Panel Validation 10110.4 Contact Us 10110.5 Disclaimer 10210.6 Bibliography 102
List of Tables1.1 List of TablesTable 1: Hepatitis B - Nomenclature of Hepatitis B 7
Table 2: Hepatitis B - Laboratory Nomenclature 15
Table 3: Hepatitis B - Approved Vaccines for Hepatitis B 19
Table 4: Hepatitis B - Approved Drugs for Hepatitis B 19
Table 5: Hepatitis B Therapeutics Market, Global, Revenue ($m), 2006 - 2011 23
Table 6: Hepatitis B Therapeutics Market, Global, Forecast ($m), 2011 - 2019 24
Table 7: Hepatitis B Therapeutics Market, The US, Revenue ($m), 2006 - 2011 25
Table 8: Hepatitis B Therapeutics Market, The US, Forecast ($m), 2011 - 2019 26
Table 9: Hepatitis B Therapeutics Market, France, Revenue ($m), 2006 - 2011 27
Table 10: Hepatitis B Therapeutics Market, France, Forecast ($m), 2011 - 2019 28
Table 11: Hepatitis B Therapeutics Market, Germany, Revenue ($m), 2006 - 2011 29
Table 12: Hepatitis B Therapeutics Market, Germany, Forecast ($m), 2011 - 2019 30
Table 13: Hepatitis B Therapeutics Market, Italy, Revenue ($m), 2006 - 2011 31
Table 14: Hepatitis B Therapeutics Market, Italy, Forecast ($m), 2011 - 2019 32
Table 15: Hepatitis B Therapeutics Market, Spain, Revenue ($m), 2006 - 2011 33
Table 16: Hepatitis B Therapeutics Market, Spain, Forecast ($m), 2011 - 2019 34
Table 17: Hepatitis B Therapeutics Market, The UK, Revenue ($m), 2006 - 2011 35
Table 18: Hepatitis B Therapeutics Market, The UK, Forecast ($m), 2011 - 2019 36
Table 19: Hepatitis B Therapeutics Market, Japan, Revenue ($m), 2006 - 2011 37
Table 20: Hepatitis B Therapeutics Market, Japan, Forecast ($m), 2011 - 2019 38
Table 21: Histological Improvement and Change in Ishak Fibrosis Score at Week 52 (007 GLOBE Study) 49
Table 22: The Results for Measures of Response Included Change in Serum HBV DNA, Change in ALT, HBeAg loss and HBeAg Seroconversion (437 Only) 51
Table 23: Changes in Ishak Fibrosis Score at Week 48 51
Table 24: Histologic Response at Week 52 Among Adult Patients Receiving Epivir-HBV 100mg Once Daily or Placebo 53
Table 25: HBeAg Seroconversion at Week 52 Among Adult Patients Receiving Epivir-HBV 100mg Once Daily or Placebo 53
Table 26: Clinical Study Results - Viread 55
Table 27: Hepatitis B Therapeutics Market, Phase III Pipeline, 2011 58
Table 28: Hepatitis B Therapeutics Market, Phase II Pipeline, 2011 59
Table 29: Hepatitis B Therapeutics Market, Phase I Pipeline, 2011 60
Table 30: Hepatitis B Therapeutics Market, Preclinical Phase Pipeline, 2011 60
Table 31: Hepatitis B Therapeutics Market, NA Phase Pipeline, 2011 60
Table 32: Hepatitis B Therapeutics, Global, Clinical Trials, 2011 63
Table 33: Hepatitis B Therapeutics, Global, Clinical Trials by Phase, 2011 64
Table 34: Hepatitis B Therapeutics, Global, Clinical Trials by Status of Development, 2011 65
Table 35: Hepatitis B Therapeutics, Global, Prominent Sponsors, 2011 66
Table 36: Hepatitis B Therapeutics, Global, Overall Sponsors, 2011 67
Table 37: Hepatitis B Therapeutics, Global, Top 10 Companies by Phase, 2011 68
Table 38: Bristol-Myers Squibb Company - Pipeline, 2011 74
Table 39: Gilead Sciences - Pipeline, 2011 75
Table 40: GlaxoSmithKline Plc. - Pipeline, 2011 76
Table 41: Other Companies - Hepatitis B Therapeutics, 2011 80
Table 42: Hepatitis B Therapeutics, Global, Deals - 2011 85
List of Figures
1.2 List of FiguresFigure 1: Genotype of Hepatitis B Virus and its Geographical Distribution 7Figure 2: Hepatitis B - Prevalence of HBV Infection in the World by Country 8Figure 3: Hepatitis B - Areas and Features of Hepatitis B Prevalence 9Figure 4: Geographic Patterns of Hepatitis B Disease Burden 10Figure 5: Structure of Hepatitis B Virus 11Figure 6: Summary of Hepatitis B Virus Characteristics 12Figure 7: Hepatitis B - Interpretation of Hepatitis B Virus Serology 15Figure 8: Hepatitis B - Life Cycle of HBV 17Figure 9: Hepatitis B - Spectrum of Liver Disease After HBV Infection 18Figure 10: Hepatitis B - Childhood Vaccination Schedule 21Figure 11: Hepatitis B Therapeutics Market, Global, Revenue ($m), 2006 - 2011 23Figure 12: Hepatitis B Therapeutics Market, Global, Forecast ($m), 2011 - 2019 24Figure 13: Hepatitis B Therapeutics Market, The US, Revenue ($m), 2006 - 2011 25Figure 14: Hepatitis B Therapeutics Market, The US, Forecast ($m), 2011 - 2019 26Figure 15: Hepatitis B Therapeutics Market, France, Revenue ($m), 2006 - 2011 27Figure 16: Hepatitis B Therapeutics Market, France, Forecast ($m), 2011 - 2019 28Figure 17: Hepatitis B Therapeutics Market, Germany, Revenue ($m), 2006 - 2011 29Figure 18: Hepatitis B Therapeutics Market, Germany, Forecast ($m), 2011 - 2019 30Figure 19: Hepatitis B Therapeutics Market, Italy, Revenue ($m), 2006 - 2011 31Figure 20: Hepatitis B Therapeutics Market, Italy, Forecast ($m), 2011 - 2019 32Figure 21: Hepatitis B Therapeutics Market, Spain, Revenue ($m), 2006 - 2011 33Figure 22: Hepatitis B Therapeutics Market, Spain, Forecast ($m), 2011 - 2019 34Figure 23: Hepatitis B Therapeutics Market, The UK, Revenue ($m), 2006 - 2011 35Figure 24: Hepatitis B Therapeutics Market, The UK, Forecast ($m), 2011 - 2019 36Figure 25: Hepatitis B Therapeutics Market, Japan, Revenue ($m), 2006 - 2011 37Figure 26: Hepatitis B Therapeutics Market, Japan, Forecast ($m), 2011 - 2019 38Figure 27: Opportunity and Unmet Need in the Hepatitis B Therapeutics Market 40Figure 28: Strategic Competitor Assessment of the Marketed Products in Hepatitis B Therapeutics, 2011 43Figure 29: Hepatitis B Therapeutics Pipeline by Phase of Clinical Development, 2011 57Figure 30: Hepatitis B Therapeutics Market, Global, Pipeline by Mechanism of Action (%), 2011 61Figure 31: Technology Trends Analytics Framework, 2011 62Figure 32: Hepatitis B Therapeutics, Global, Clinical Trials by Country, 2011 63Figure 33: Hepatitis B Therapeutics, Global, Clinical Trials by Phase (%), 2011 64Figure 34: Hepatitis B Therapeutics, Global, Clinical Trials by Status of Development (%), 2011 65Figure 35: Hepatitis B Therapeutics, Global, Prominent Sponsors (%), 2011 66Figure 36: Hepatitis B Therapeutics, Global, Overall Sponsors (%), 2011 67Figure 37: Hepatitis B Therapeutics, Global, Top 10 Companies by Phase, 2011 68Figure 38: Hepatitis B Therapeutics Market, Drivers and Restraints, 2011 70Figure 39: Implications for Future Market Competition in the Hepatitis B Therapeutics Market, 2011 70Figure 40: Hepatitis B Therapeutics Market, Clinical Pipeline by Company, 2011 72Figure 41: GlobalData Market Forecasting Model 100
Companies MentionedBristol-Myers Squibb CompanyGilead Sciences
GlaxoSmithKline Plc
F. Hoffmann-La Roche
Merck & Co. Inc.
Novartis AG
To order this report:Therapy Industry: Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker